Ross A. Baker
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Schizophrenia research and treatment, Treatment of Major Depression, Bipolar Disorder and Treatment, Health Systems, Economic Evaluations, Quality of Life, Attention Deficit Hyperactivity Disorder
Most-Cited Works
- → Differential expression of the beta2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help(1997)430 cited
- → Activated T helper 1 and T helper 2 cells differentially express the beta-2-adrenergic receptor: a mechanism for selective modulation of T helper 1 cell cytokine production(1997)211 cited
- → Prevalence and Predictors of Lipid and Glucose Monitoring in Commercially Insured Patients Treated With Second-Generation Antipsychotic Agents(2009)184 cited
- → Digital health technology for use in patients with serious mental illness: a systematic review of the literature(2017)180 cited
- → Neurotransmitter-specific uptake and retrograde transport of [3H]glycine from the inferior colliculus by ipsilateral projections of the superior olivary complex and nuclei of the lateral lemniscus(1990)175 cited
- → Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia(2015)157 cited
- → Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study(2014)151 cited
- → Clinical Implications of Antipsychotic-Induced Hyperprolactinemia in Patients With Schizophrenia Spectrum or Bipolar Spectrum Disorders(2007)149 cited
- → Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials(2019)147 cited
- → Aripiprazole Once-Monthly in the Acute Treatment of Schizophrenia(2014)103 cited